Federal Circuit Grants Panel Rehearing In Label Carve-Out Row
WASHINGTON, D.C. — In a two-page order issued Feb. 10, the Federal Circuit U.S. Court of Appeals announced that it will revisit its October 2020 finding that Teva Pharmaceuticals USA Inc....To view the full article, register now.
Already a subscriber? Click here to view full article